"A meeting was held between NICE and the company in early-February regarding next steps for the appraisal of DCVax-L for treating glioblastoma, and more information will be available in due course. NICE will continue liaising with the company and monitoring timelines."
The next step is for NWBO to send in their evidence submission.
Directly from NICE, dated today:
"The next step would be for the company to let us know when they would be able to send an evidence submission to NICE. There is no further update at present."
Market Data 
Markets 
